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ABSTRACT
Nonviral integration systems are widely used
genetic tools in transgenesis and play increasingly
important roles in strategies for therapeutic gene
transfer. Methods to efficiently regulate the activity
of transposases and site-specific recombinases
have important implications for their spatiotemporal
regulation in live transgenic animals as well as for
studies of their applicability as safe vectors for
genetic therapy. In this report, strategies for post-
translational induction of a variety of gene-inserting
proteins are investigated. An engineered hormone-
binding domain, derived from the human progester-
one receptor, hPR891, and specifically recognized
by the synthetic steroid mifepristone, is fused to the
Sleeping Beauty, Frog Prince, piggyBac and Tol2
transposases as well as to the Flp and (C31
recombinases. By analyzing mifepristone-directed
inducibility of gene insertion in cultured human
cells, efficient posttranslational regulation of the
Flp recombinase and the (C31 integrase is docu-
mented. In addition, fusion of the (C31 integrase
with the ER
T2 modified estrogen receptor hormone-
binding domain results in a protein, which is
inducible by a factor of 22-fold and retains 75% of
the activity of the wild-type protein. These inducible
(C31 integrase systems are important new tools in
transgenesis and in safety studies of the (C31
integrase for gene therapy applications.
INTRODUCTION
Nonviral integration systems, including DNA transposons
and site-speciﬁc recombinases (SSRs), are widely used
genetic tools for genome mutagenesis and transgenesis
(1–3). Desirable properties such as simple and inexpen-
sive production, together with the lack of induction of
immunological responses and improved safety, have made
nonviral integration systems become widespread alter-
natives to viral integration systems for therapeutic gene
transfer applications (4,5).
DNA transposons are mobile DNA elements that can
move from one genetic location to another through a cut
and paste mechanism. Transposon-based vector systems
consists of a donor plasmid harboring the transgene of
interest placed between terminal inverted repeats (IRs)
of the transposon and a helper plasmid carrying the
transposase-coding sequence under the control of a
promoter. Codelivery of donor and helper plasmids will
facilitate integration of the transgene into the genome of
cells (6). Sleeping Beauty (SB) and Frog prince (FP),
members of the Tc1/mariner family of transposable
elements, were constructed from inactive transposon
elements residing in the genomes of salmonid ﬁsh and
the Northern leopard frog (Rana pipiens), respectively
(7,8) and both transpose eﬃciently in vertebrate cells.
Recently, two natural transposable elements, piggyBac
(PB) isolated from the genome of the cabbage looper
moth Trichoplusia ni, and Tol2,ahAT-like transposable
element isolated from the genome of the Japanese medaka
ﬁsh Oryzias latipes, have shown to have activity in
mammalian cells (9–14). PB has been used previously
for genetic analysis in a wide variety of insects (11),
whereas Tol2 has been used mainly for germline transgen-
esis in zebraﬁsh (13).
SSRs can induce deletion, insertion or inversion of DNA
sequences by breaking and joining DNA molecules at
speciﬁc sites (1). The tyrosine recombinase Flp, originating
from the yeast Saccharomyces cerevisiae, mediates recom-
bination between two 34bp homotypic Flp recombination
target (FRT) sequences. Flp has, along with its family
member the Cre recombinase, been used in numerous
gene modiﬁcation studies in mammalian animals and
cells (15–17). Another SSR, the serine recombinase C31
integrase, encoded by a phage of Streptomyces lividans
(18), recognizes the 34- and 39-heterotypic sequences
attB and attP. Recombination results in generation of
two hybrid sites, attL and attR, and the reaction is
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site-speciﬁc integration of a plasmid containing an attB
sequence into speciﬁc chromosomal sequences, called
pseudo attP sites, in human and mouse cells (20).
The total number of pseudo attP sites present in the
mammalian genome is estimated to be in the range of
100–1000 sites, and the ability of the C31 integrase to
integrate DNA into such sites in unmodiﬁed mammalian
genomes has made this recombinase system become
a promising vector system for somatic gene therapy
approaches (21,22).
Among several attempts to further improve nonviral
integration systems, mutational analysis of the SB trans-
posase and the Flp recombinase have given rise to several
hyperactive mutants with increased activity in vertebrate
cells (23–26), whereas a C31 integrase with increased
speciﬁcity for a single pseudo attP site has been created by
DNA shuﬄing (27). In addition, SB transposase fusion
variants with altered functional properties have been
generated recently in attempts to increase the site-
speciﬁcity of the integration systems (28,29). Alternative
ways to improve these systems further include develop-
ment of strategies for inducible recombination and gene
insertion. Regulation at the level of expression by using
inducible promoters is an obvious possibility, although
this approach is often hampered by leaky expression.
Regulation of the activity at the posttranslational level will
allow temporal control of the transposition or recombina-
tion reaction, and this will be an advantage in studies
where transposition or recombination is required at a
certain point or within a certain time span. Inducible
recombinase systems have previously been developed by
fusion of the recombinase to the regulatory domain of a
steroid receptor (30,31). Cre and Flp recombinases fused
to the modiﬁed estrogen receptor hormone-binding
domain, ER
T2, demonstrated hormone-dependent recom-
bination with high activity in the presence of the receptor
ligand, 4-hydroxytamoxifen (4-OHT) and low activity
when 4-OHT was absent (32,33). By using mice transgenic
for the Cre-ER
T2 gene driven by tissue-speciﬁc promoters,
tamoxifen-induced spatiotemporally regulated transgene
expression has been reported in a range of cell types,
including adipocytes (34), melanocytes (35), gut epithelial
cells (36), hepatocytes (37), astroglial cells (38,39) and
nociceptive neurons of dorsal root ganglia (40). An
inducible Cre recombinase has also been obtained by
fusion to the hormone-binding domain of the mutant
human progesterone receptor hPR891 (41). The hPR891
contains a 42 amino acid C-terminal deletion, which
makes the receptor bind speciﬁcally to the synthetic
steroid mifepristone (RU486) and not to progesterone or
other endogenous hormones (42). Mifepristone-regulated
activity of this fusion has been utilized for spatiotemporal
control of gene expression in brain (43) and skin (44).
In this study, we used the hormone-binding domain
(here referred to as ‘MiBD’ for ‘Mifepristone-binding
domain’) of hPR891 to generate fusion proteins with the
SB, FP, PB and Tol2 transposases and the Flp and C31
recombinases in an attempt to develop inducible nonviral
integration systems. We demonstrate that engineered
high-eﬃciency fusion variants of the Flp and C31
recombinases mediate site-directed gene insertion in the
presence of mifepristone and show low levels of activity in
the absence of the drug. Finally, we show that fusion of
another hormone-binding domain, the ER
T2 domain, to
the C31 integrase also results in the creation of an
inducible integrase. We expect that these new inducible
C31 integrase systems will be of great utility in
transgenesis and as a tool for studies of safety features
of the C31 system for therapeutic gene transfer.
MATERIALS AND METHODS
Plasmid construction
The Flp coding region [corresponding to enhanced Flp
variant, Flpx9, derived from ref. (26)] was PCR-ampliﬁed
from pHD.SB.Flp (45) and inserted into pBSKS
 .CMV-
hAAT (46), generating pCMV-Flpx9. The pFRT-hygro.
PGK-puro (pLV/FRT-hygro) was previously described in
(Moldt,B., Staunstrup,N.H., Jakobsen,M., Yanez-
Munoz,R.J. and Mikkelsen,J.G., unpublished data). To
generate pCMV-Flpx9.MiBD and pCMV-MiBD.Flpx9,
two in-frame fusion constructs were made by overlap
extension PCR of a 753-bp MiBD PCR fragment
ampliﬁed from pT7bhPRB-891 (42) and a 1272-bp Flpx9
PCR fragment ampliﬁed from pCMV-Flpx9, and the two
fusion constructs were subsequently cloned into NheI-
digested pCMV-Flpx9. A short linker with the sequence
50-GCCGGC-30 connects the MiBD and Flpx9 sequences
in the fusion constructs. The pUC.CMV-HSB3 was
generated by ligation of a 1023-bp HSB3 PCR fragment,
ampliﬁed from pCMV-HSB3 (25), into SacII-digested
pCMV-SB (47). In pUC.CMV-HSB3 the HSB3 sequence
is ﬂanked by a NotI site and a PacI site. The two plasmids
pCMV-HSB3.L1.MiBD and pCMV-MiBD.L1.HSB3
contain fusion constructs made by in-frame PCR ligations
of a 753-bp MiBD PCR fragment ampliﬁed from
pT7bhPRB-891 and a 1023-bp HSB3 PCR fragment
ampliﬁed from pCMV-HSB3. The two fusion constructs
were digested with NotI and PacI and cloned into double-
digested pUC.CMV-HSB3. A short linker (Linker 1) with
the sequence 50-CCCGGGGGAGGAACTAGT-30 con-
nects the MIBD and HSB3 sequences in the fusion
constructs. The pSBT/PGK-puro plasmid, previously
referred to as pTpuro, was previously described (48).
The pCMV-FP plasmid was constructed by inserting the
FP transposase open reading frame, PCR-ampliﬁed from
pFV-FP (8), into SacII-digested pCMV-SB. To generate
pCMV-FP.L1.MiBD the 1023-bp FP transposase gene
from pCMV-FP was ampliﬁed by PCR and cloned in-
frame into NotI/XmaI-digested pCMV-HSB3.L1.MiBD.
The pCMV-MiBD.L1.FP plasmid was made by in-frame
ligation of the FP gene into SpeI/PacI-digested pCMV-
MiBD.L1.HSB3. To construct pFPT/PGK-puro, an over-
lap PCR product containing the left FP IR, ampliﬁed
from pFP-neo (8) and the PGK-puro cassette, ampliﬁed
from pSBT/PGK-puro, was inserted into KpnI/NotI-
digested pSBT/PGK-puro. The right FP IR sequence,
ampliﬁed by PCR from pFP-neo, was inserted into the
resulting plasmid digested with NotI and SalI to
generate pFPT/PGK-puro. The pCMV-PB and
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the 1785-bp PB transposase gene from p3X3P-DsRed1
and the 1950-bp Tol2 gene from pCAGGS-T2TP (12) and
subsequent ligation of the PCR fragments into NotI/
PacI-digested pUC.CMV-HSB3. The four plasmids
pCMV-PB.L1.MiBD, pCMV-MiBD.L1.PB, pCMV-
Tol2.L1.MiBD and pCMV-MiBD.L1.Tol2 were con-
structed by ligation of the PB and Tol2 transposase genes
into NotI/XmaI-digested pCMV-HSB3.L1.MiBD and
SpeI/PacI-digested pCMV-MiBD.L1.HSB3. To construct
pPBT/PGK-puro a PGK-puro cassette was ampliﬁed from
pSBT/PGK-puro by PCR, digested with KpnI and NotI
and cloned into double-digested pXL-BacII (49). The
pTol2T/PGK-puro plasmid was made by cloning a NheI/
BsrGI-digested PGK-puro cassette into double-digested
pT2AL200R150 (13). To generate pCMV-C31, the 1842-
bp C31 integrase gene was ampliﬁed by PCR from
pCMV-Int (18) and ligated into NotI/PacI-digested
pUC.CMV-HSB3. The pCMV-C31.L2.MiBD plasmid
was made by ligation of the C31 integrase gene into
NotI/SpeI-digested pCMV-HSB3.L1.MiBD. The pCMV-
MiBD.L2.C31 plasmid contains a MiBD-C31 fusion
construct that was made by in-frame PCR ligation of a
MiBD PCR fragment ampliﬁed from pT7bhPRB-891 (42)
and a C31 PCR fragment ampliﬁed from pCMV-Int.
To generate pCMV-MiBD.L2.C31, the MiBD-C31
fusion construct was ligated into NotI/PacI-digested
pUC.CMV-HSB3. Both the pCMV-C31.L2.MiBD plas-
mid and the pCMV-MiBD.L2.C31 plasmid have a short
linker (Linker 2), with the sequence 50-ACTAGT-30,
between the C31 integrase and the MiBD sequences.
To generate pAttB/PGK-puro, the 293-bp attB sequence
was ampliﬁed by PCR using p11 (22) as template and
cloned into EcoRI-digested pSBT/PGK-puro in which the
left IR sequence was removed upon insertion of the attB
sequence. The pCMV-MiBD.L2.HSB3 was made by
insertion of the PCR-ampliﬁed HSB3 sequence into SpeI/
PacI-digested pCMV-MiBD.L2.C31. The pCMV-
MiBD.L1.C31 plasmid contains a MiBD-C31 fusion
construct with the linker 50-CCCGGGGGAGGAA
CTAGT-30. The fusion construct was made by in-frame
PCR ligation of a MiBD PCR fragment and a C31
PCR fragment. To generate pCMV-MiBD.L1.C31 the
MiBD-C31 fusion construct was ligated into NotI/
PacI-digested pCMV-C31.L2.MiBD. The pCMV-
C31.L2.ER
T2 plasmid was made by insertion of an
ER
T2 PCR fragment, ampliﬁed from pCre-ER
T2 (30), into
SpeI/PacI-digested pCMV-C31.L2.MiBD. The plasmid
pCMV-mC31 (pCMV-mINT) has been described pre-
viously (22). All produced DNA constructs were veriﬁed
by restriction digestion and DNA sequencing.
Integration analyses
HeLa (human cervical cancer cells), HEK-293 (human
embryonal kidney cells), Hep1A (mouse hepatoma cells)
and Flp-In T-Rex HEK-293 cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum, 1% penicillin–
streptomycin and 1% glutamine. For treatment with
mifepristone, the medium was further supplemented with
500nM mifepristone (Sigma-Aldrich, St Louis, MO,
USA) on the day prior to transfection.
HeLa cells were plated at 2 10
5cells/well in 6-well
dishes 1day before cotransfection with (i) a donor plas-
mid, containing a PGK-puro cassette situated in a trans-
poson or together with an attB sequence and (ii) a helper
plasmid encoding the diﬀerent transposases or the C31
integrase. Transfections were carried out using FuGene-6
(Roche, Basel, Switzerland) according to the manufac-
turer’s instructions using 3ml of reagent per 2mg of DNA.
One microgram of helper plasmid plus 1mg sub-
strate plasmid was used in each transfection. In negative
control experiments, pcDNA3.1D/V5.TOPO (Invitrogen,
Carlsbad, CA, USA) was transfected instead of the helper
plasmid. In the dose–response assay and the ﬁnal
comparison of pCMV-C31.L2.MiBD and pCMV-
C31.L2.ER
T2, 1.5mg of each helper and substrate
plasmid was transfected using 6ml FuGene-6. One day
after transfection, fresh medium was added to the cells.
Two days after transfection, cells were split to varying
densities and plated in 10-cm dishes. Three days after
transfection, selection medium containing 1mg/ml pur-
omycin (Sigma-Aldrich) was added to the cells. After 10
days of selection, colonies of cells were stained with
methylene blue, air-dried and counted. For analysis of the
mifepristone dose–response transfected cells were incu-
bated in medium containing from 0 to 2mM mifepristone.
The activity of the Flp recombinase fusion proteins was
quantiﬁed as integration events in cultured Flp-In T-REx
293 cells (Invitrogen). Cells were seeded at 5.5 10
5
cells/dish in 10-cm dishes the day before cotransfection
with pFRT-hygro.PGK-puro and diﬀerent Flp recombi-
nase-expressing plasmids. One hour before transfection,
fresh medium was added to the cells. Transfection was
performed using calcium-phosphate coprecipitation, and
in each transfection 1mg pFRT-hygro.PGK-puro plus
10mg recombinase plasmid was used. Three hours post-
transfection, the medium was refreshed. Two days after
transfection, cells were diluted (1:50 and 1:100) and seeded
in 10-cm dishes. Three days after transfection, selection
medium containing 1mg/ml puromycin (Sigma-Aldrich) or
200mg/ml hygromycin B (Invitrogen) was added to the
cells, and after 10 days of selection colonies were stained in
0.6% methylene blue, air-dried and counted.
b-galactosidaseassays
The recombinogenic activity of Flp variants was measured
by monitoring expression of b-galactosidase in HEK-293
and Hep1A cells cotransfected (by calcium-phosphate
treatment) with 17mg Flp-encoding plasmid DNA and
2mg of the reporter construct, pneobgal (Stratagene,
San Diego, CA, USA). Cells were seeded at 1 10
4cells/
cm
2 in 10-cm dishes on the day prior to transfection. The
concentration of b-galactosidase in cell lysates was
determined using a bgal ELISA kit (Roche).
Detectionof integration at pseudoattPsite 19q13.31
The ability of the C31.MiBD fusion protein to recognize
the pseudo attP site, 19q13.31, was investigated using
cultured HEK-293 cells. HEK-293 cells were plated at
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5cells/well in 6-well dishes on the day before
transfection. A total of 1.5mg of pAttB/PGK-puro
together with 1.5mg pCMV-C31 or pCMV-
C31.MiBD were transfected into the cells using
FuGene-6 reagent, with 6ml reagent per 3mg DNA. One
day posttransfection fresh medium was added to the cells.
The cells transfected with pCMV-C31.MiBD plasmid
received medium supplemented with 500nM mifepristone.
Two days posttransfection, cells were diluted 1/50 and
seeded in 10-cm dishes. Three days posttransfection,
selection was applied using medium containing 1mg/ml
puromycin. After 10 days of selection, puromycin-
resistant colonies were trypsinized and collected in pools.
Ten pools were grown to conﬂuency and genomic DNA
was extracted. A two-step nested PCR was performed on
genomic DNA to detect integration in the pseudo site
19q13.31. Vector- and locus-speciﬁc primers were utilized
in both PCR steps. The vector-speciﬁc primer for the ﬁrst
PCR was 50-CAGGTACCGTCGACGATGTA-30 and for
the second PCR 50-CGATGTAGGTCACGGTCTCGA-
30. Four genomic primers were designed using the genome
database using the UCSC genome browser. First- and
second-PCR primers were designed for both the plus
strand and the minus strand, in order to detect plasmid
integration in both orientations. The plus strand primers
were 50-CATGAGGTGACTGCAGCTTGA-30 for the
ﬁrst PCR and 50-GATAAGGAATGTGCTGTGCTT-30
for the second PCR. The minus strand primers were
50-GCTGCATACTGGGCTACACGT-30 for the ﬁrst
PCR and 50-ATATAGGTTTCAATGAACCTT-30 for
the second PCR. Primers were designed to give bands at
a size of 350bp. In the ﬁrst PCR reactions, 100–400ng of
genomic DNA was used. Two microliters of the ﬁrst-
round PCR products were then used as template in the
second-round PCR. In both PCR steps, 40 cycles and an
annealing temperature of 578C were used. Products of the
second PCR products were subjected to agarose gel
electrophoresis, and bands of the expected size were
excised, puriﬁed using Gel Extraction Kit (Omega Bio-
Tek, Doraville, GA, USA) and sequenced using the
primer 50-CGATGTAGGTCACGGTCTCGA-30.
Statistical analysis
Statistical analyses were performed using unpaired t-tests,
except when diﬀerent variances were detected by an F-test,
in which case statistical analyses were performed using the
Mann–Whitney U-test.
RESULTS
Mifepristone promotes posttranslational induction
ofafusion variantof theFlp recombinase
Previous studies of tyrosine recombinases, like Cre and
Flp, C-terminally fused to genetically engineered steroid-
binding domains have demonstrated robust hormone-
induced recombination activities (30,31,41). Hence, Cre
and Flp recombinases fused to the ER
T2 estrogen receptor
hormone-binding domain are highly responsive to 4-OHT
(30,32), whereas the activity of Cre fused to part of the
human progesterone receptor can be regulated by
mifepristone. To explore further the inducibility of
tyrosine recombinases, we initially designed a variant of
the Flp recombinase [based on the enhanced Flpx9 variant
created by Buchholz et al. (26)], containing a C-terminal
MiBD (Figure 1A). The activity of this variant, expressed
from pCMV-Flpx9.MiBD, was ﬁrst analyzed by transient
recombination assays in which pCMV-Flpx9.MiBD was
cotransfected with the reporter plasmid pneobgal
(Figure 1B). Upon Flp recombination, the neo expression
cassette, situated within the bgal reporter gene, was
removed from the construct, allowing expression of a
functional bgal-FRT fusion variant (50). We ﬁrst tested the
sensitivity of the transient reporter assay by transfecting
HEK-293 cells with 2mg pneobgal and increasing amounts
of pCMV-Flpx9. A linear increase in the b-gal concentra-
tion measured in the cell lysate was detected using in the
range from 8 to 24mg of pCMV-Flpx9.MiBD (data not
shown). In subsequent experiments, 17mg of Flp-encoding
plasmid and 2mg pneobgal was transfected into human
HEK-293 cells and Hep1A mouse liver cells, respectively.
In both cell lines, the activity of Flpx9.MiBD fusion
variant was strongly enhanced in the presence
of mifepristone. The activity of the drug-induced
Flpx9.MiBD was in both cell lines close to 50% of the
activity of the unfused Flpx9 variant (Figure 1C). More-
over, in the absence of mifepristone the fusion variant was
inactive and resulted in levels of b-gal production close to
the background measured when pneobgal was cotrans-
fected with pUC19 (negative control). Throughoutthis and
subsequent experiments, mifepristone in control experi-
ments did not aﬀect the activity of the wild-type recom-
binases (data not shown), indicating that the drug did not
directly inﬂuence the transfected cells or the recombination
processes catalyzed by uninducible recombinases.
Based on our ﬁndings, we investigated whether the
mifepristone-responsive Flpx9.MiBD variant could facil-
itate drug-inducible gene insertion. To test the overall
ﬂexibility of regulated Flp variants, we also generated an
alternative fusion variant, MiBD.Flpx9, in which MiBD
had been fused to the N-terminus of Flp. Constructs
encoding the diﬀerent Flp variants were cotransfected
with pFRT-hygro.PGK-puro into HEK-293-derived cells
containing an FRT docking vector (Figure 1D). In this
set-up, only site-directed plasmid insertion mediated by
Flp-directed recombination between the FRT site on
pFRT-hygro.PGK-puro and the FRT site within the
genomic docking vector would reconstitute a functional
hygromycin B resistance expression cassette, allowing
selection for Flp-mediated insertion events. In addition,
by including a PGK-driven puromycin resistance gene on
the plasmid we could compare the eﬃciency of plasmid
insertion by Flp-mediated and random insertion, respec-
tively. As measured by the number of hygromycin
B-resistant colonies the activity of Flpx9 and mifepris-
tone-induced Flpx9-MiBD did not diﬀer statistically
(P=0.128) (Figure 1E). However, by selecting transfected
cells with puromycin the activity of the induced protein
was signiﬁcantly lower than the wild-type Flpx9
(P=0.005). In this setup, we measured mifepristone-
induced insertion at a level approaching 60% of the
unfused Flp (Figure 1F). We also detected a high overall
e67 Nucleic Acids Research, 2008, Vol. 36, No. 11 PAGE4 OF12Figure 1. Mifepristone-inducible Flp recombinase mediates gene excision and insertion. (A) Schematic representation of the expression cassette
encoding Flpx9 and Flpx9.MiBD. In the Flpx9-MiBD fusion construct, the two domains were separated by a short 6-bp linker (encoding Ala and
Gly), indicated by the white box. (B) Schematic representation of b-gal reporter construct used for detection of Flp activity. The pneobgal contains a
neomycin resistance expression cassette (driven by the TK promoter) ﬂanked by FRTs indicated by black arrows. Upon Flp-directed recombination
between the two FRT sites a functional b-gal-FRT gene is established, and b-gal protein can be detected by ELISA. (C) Mifepristone-induced Flp
recombination in HEK-293 and Hep1A cells. Two micrograms of pneobgal was cotransfected with 17mg of the indicated Flp variant (or pUC19 in
case of the negative control) in the presence of 300mM mifepristone. Presence and absence of mifepristone is indicated below the columns by + and
 , respectively. The b-gal concentration in cell lysates, harvested 24h posttransfection, was determined by ELISA and normalized to the total protein
content in the sample. (D) Schematic representation of Flp-mediated integration of FRT donor plasmid into the FRT docking site in Flp-In T-Rex
293 cells. pFRT-hygro.PGK-puro contains both a promoterless, ATG-deﬁcient hygromycin B resistance gene and a puromycin resistance gene driven
by a PGK promoter. Upon Flp-directed recombination between the FRT site in the donor plasmid and the FRT docking site in the HEK-293-
derived cells a functional hygromycin B resistance expression cassette is reconstituted, allowing selection for Flp-mediated insertion events with
hygromycin B. (E) and (F) Mifepristone-induced gene insertion by the Flp recombinase in FRT-tagged HEK-293-derived cells. One microgram of
pFRT-hygro.PGK-puro was co-transfected with 10mg Flp-encoding plasmid into Flp-In T-REx 293 cells. Cells were selected by treatment with
hygromycin B or puromycin for 10 days before counting colonies. A total of 1.9 10
3 5.7 10
2 hygromycin B-resistant colonies and
8.9 10
3 6.6 10
2 puromycin-resistant colonies was obtained per transfection with pCMV-Flpx9. The activity of the Flp variants tested is
presented as percentage of activity relative to the wild-type recombinase. All experiments were performed in triplicates. The asterisks indicate
signiﬁcant diﬀerences between relevant groups (P<0.05).
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which most likely resulted from the high-transfection rate
and resulting random gene insertion in HEK-293 cells.
Nevertheless, the number of puromycin-resistant colonies
was signiﬁcantly higher in the presence of mifepristone
(P=0.003) conﬁrming that the Flpx9.MiBD recombinase
was robustly induced by the drug. In summary, our data
conﬁrm tight steroid-regulated activity of genetically
engineered tyrosine recombinases, as shown here for the
ﬁrst time with a mifepristone-induced variant of Flp, and
demonstrate eﬃcacy of posttranslationally regulated gene
insertion by site-directed nonviral recombinases.
Limited mifepristone-mediated induction of
MiBD-containing DNA transposase
fusionvariants
Tyrosine recombinases fused to steroid-binding domains
appear to possess structural and functional properties that
allow speciﬁc binding of steroids and eﬃcacious induction
of catalytic activity in the presence of the relevant drugs.
We were attracted by the possibility of regulating other
prominent nonviral gene insertion technologies at the
posttranslational level using a similar steroid-based
regulation approach. We therefore set out to test the
potential to induce activities of four diﬀerent transposases
derived from the SB, FP, Tol2 and PB transposons, which
are all highly transposable in mammalian cells. The
transposase coding sequences of all four elements were
inserted either upstream or downstream from the MiBD
sequence in the context of expression cassettes driven by
the cytomegalovirus (CMV) promoter, allowing expres-
sion of transposases fused C- and N-terminally, respec-
tively, with MiBD. In all constructs, the fused transposase
and MiBD were separated by a 6-amino acid ﬂexible
linker (Linker 1, L1, PGGGTS) consisting of three glycine
residues ﬂanked by amino acids encoded by the restriction
sites separating the two domains (Figure 2A).
For studies of Tc1/mariner transposases, we fused the
coding sequence of HSB3, a hyperactive version of the SB
transposase (25), with MiBD, generating pCMV-HSB3.
L1.MiBD and pCMV-MiBD.L1.HSB3. In separate trans-
fections, plasmid DNA encoding the diﬀerent transposase
variants was introduced into HeLa cells together with
pSBT/PGK-puro, a plasmid containing a PGK-driven
puromycin resistance gene cassette ﬂanked by SB-derived
inverted repeats. After transfection, the cells were selected
with puromycin. As evident in Figure 2B neither HSB3.
L1.MiBD nor MiBD.L1.HSB3 protein showed signiﬁcant
transposition activity in the presence or absence of
mifepristone. The activity of MiBD.L1.HSB3 was  10%
of unfused HSB3 but the fusion protein did not respond to
mifepristone. Likewise, N- and C-terminal fusion variants
of the FP transposase, did not catalyze eﬃcient insertion
of a FP transposon carrying the PGK-puro cassette (data
not shown).
We next investigated the transposition activities of the
Tol2 transposase fused C- and N-terminally to MiBD by
cotransfecting plasmid DNA encoding Tol2 transposase
variants with pTol2T/PGK-puro carrying the PGK-puro
expression cassette in the context of a Tol2 transposon.
The C-terminal fusion of Tol2, Tol2.L1.MiBD, retained
 40% the activity of the wild-type Tol2 transposase in the
presence of mifepristone (Figure 2C). In the absence of
mifepristone, a reduced level of transposition was
observed, which diﬀered statistically from the level
obtained with mifepristone (P=0.004). However, the
protein retained substantial drug-independent activity and
the level of inducibility was low. The N-terminal fusion
variant of the Tol2 transposase was completely inactive
and not inducible by mifepristone. In a similar fashion,
low levels of induction were monitored with PB transpo-
sases fused N- and C-terminally with MiBD and cotrans-
fected with plasmid DNA, pPBT/PGK-puro, containing
the PGK-puro cassette in the context of a PB transposon
(data not shown).
In summary, of the tested transposase fusion variants
with the L1 linker, only the Tol2 fusion was signiﬁcantly
induced in the presence of mifepristone. Although this
variant, in particular, showed some activity, the level of
induction was at best modest due to robust activity of the
protein in the absence of the drug.
Gene insertion by a(C31recombinase C-terminally fused
with MiBD isinducible and does notpossess activity above
background level in theabsence of mifepristone
The C31 recombinase belongs to the family of serine
recombinases, which acts through mechanisms of catalysis
(involving the catalytic serine) that diﬀer from the
mechanisms of the tyrosine recombinases like Cre and
Flp (51). The C31 recombinase is a high molecular
weight serine recombinase with a catalytic domain
situated very close to the N-terminus, a ﬂanking DNA-
binding domain and a region containing several conserved
cysteines required for recombinogenic activity of the
protein. For comparison, the catalytic domains of Cre
and Flp are located in the C-terminal part of the proteins.
Despite structural and mechanistic diﬀerences we wanted
to explore whether MiBD-containing variants of the
C31 integrase could be induced when treating target
cells with mifepristone. We initially constructed fusion
variants containing a 2-amino acid linker (Linker 2, L2)
encoded by the cloning linker situated between the
integrase and MiBD sequences (Figure 2D). We cotrans-
fected plasmids encoding these variants with a plasmid,
pAttB/PGK-puro, carrying both attachment site B (attB)
and the PGK-puro gene cassette, into HeLa cells and
counted colonies formed after puromycin selection. Both
MiBD-tagged versions of the integrase, C31.L2.MiBD
and MiBD.L2.C31 were completely inactive in the
absence of mifepristone (Figure 2E). Whereas the activity
of MiBD.L2.C31 did not improve in the presence of
mifepristone, C31.L2.MiBD proved to be highly induc-
ible when adding mifepristone to the medium. Hence, the
presence of mifepristone triggered a 28-fold increase in
activity over background (P=0.003), resulting in a
protein that possessed  40% the activity of the unfused
C31 integrase (Figure 2E). In addition, a dose–response
experiment demonstrated that the C31.L2.MiBD pro-
tein is responsive to even small amounts of mifepristone,
indicating that the system is highly sensitive (Figure 2F).
e67 Nucleic Acids Research, 2008, Vol. 36, No. 11 PAGE6 OF12Figure 2. Variable levels of mifepristone-induced gene insertion by posttranslationally induced transposases and recombinases. (A) Schematic
representation of transposase fusion constructs containing the transposase open reading frame fused 30 or 50 with the sequence encoding the MiBD.
Expression of C- or N-terminally tagged fusion variants was driven by a CMV promoter (white arrow). The two protein domains were separated by
a short ﬂexible 6-amino acid linker (linker 1, Pro-Gly-Gly-Gly-Thr-Ser), indicated by the white box. (B) and (C) Activity of fusion variants, derived
from the hyperactive Sleeping Beauty transposase HSB3 and the Tol2 transposase, in HeLa cells. One microgram of plasmid DNA encoding CMV-
driven SB or Tol2 transposase variants was cotransfected with 1mg pSBT/PGK-puro or pTol2/PGK-puro, respectively. MiBD-fusion variants were
analyzed in the presence of 500nM mifepristone (indicated by ‘+’) or in the absence of mifepristone (indicated by ‘ ’). The activity of each variant is
presented relative to the activity of the wild-type transposase. A total of 1.3 10
4 4.5 10
3 and 1.3 10
4 3.1 10
3 puromycin-resistant colonies
were obtained per transfection with pCMV-HSB3 and pCMV-Tol2, respectively. All experiments were performed in triplicates. The asterisks indicate
signiﬁcant diﬀerences between relevant groups (P<0.05). (D) Schematic representation of C31-based fusion constructs containing the C31 gene
fused 30 or 50 with the sequence encoding the MiBD. Expression of C- or N-terminally tagged fusion variants was driven by a CMV promoter (white
arrow). The two protein domains were separated by a short 2-amino acid linker (linker 2, Thr-Ser), indicated by the white box. (E) Activity of fusion
variants, derived from the C31 integrase, in HeLa cells. One microgram of plasmid DNA encoding CMV-driven C31 integrase variants was
cotransfected with 1mg pAttB/PGK-puro. MiBD-fusion variants were analyzed in the presence of 500nM mifepristone (indicated by ‘+’) or in the
absence of mifepristone (indicated by ‘ ’). The activity of each variant is presented relative to the activity of the wild-type recombinase. A total of
1.3 10
3 2.0 10
2 puromycin-resistant colonies were obtained per transfection with pCMV-C31. All experiments were performed in triplicates.
(F) Mifepristone dose–response assay in HeLa cells. One and a half microgram of plasmid DNA encoding the inducible C31 integrase (pCMV-
C31.L2.MiBD) was cotransfected with 1.5mg pAttB/PGK-puro in the presence of increasing concentrations of mifepristone. Levels of induction are
presented by the exact number of puromycin-resistant colonies obtained after selection. (G) Activity of HSB3 transposase and C31 integrase fusion
variants containing the L1 or L2 linker. One microgram of plasmid DNA encoding MiBD-HSB3 or C31-MiBD fusion proteins containing either
L1 or L2 was cotransfected in HeLa cells with 1mg pSBT/PGK-puro or pAttB/PGK-puro, respectively. The fusion variants were analyzed in the
presence of 500nM mifepristone (indicated by ‘+’) or in the absence of mifepristone (indicated by ‘ ’). The activity of each variant is presented
relative to the activity of the wild-type (wt) recombinase. All transfections were performed as three independent experiments.
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of mifepristone-directed inducibility of transposases
and recombinases. As the linkers that were used to
couple the hormone-binding domain with the catalytic
protein diﬀered in length and composition, we constructed
a MiBD-HSB3 fusion variant with an intervening L2
sequence. As shown in Figure 2G, both MiBD.L1.HSB3
and MiBD.L2.HSB3 variants were inactive and did not
respond to mifepristone. In contrast, the C31-derived
fusion variants (C31.L1.MiBD and C31.L2.MiBD)
containing either of the two linkers were both inactive in
the absence of mifepristone and highly induced in cells
treated with the drug (Figure 2G). These data suggest that
the composition of the linkers used in the fusion proteins
was not the prime cause of the diﬀerent responses to
mifepristone.
As shown by diﬀerences in inducibility (relative number
of colonies obtained in the presence and absence of
mifepristone) (Figure 3), the C-terminal fusion variant of
the C31 recombinase proved in our hands to be the most
tightly mifepristone-regulated gene-inserting protein and
was studied, therefore, in further detail.
Induced (C31.MiBD recombinase mediates site-directed
geneinsertion into aknown hotspot inhuman cells
The C31 integrase mediates site-speciﬁc recombination
between the attB site on the vector plasmid and pseudo-
attP sites dispersed throughout the human genome
(18,20). Hotspot insertion sites have been identiﬁed in
human cells including HEK-293 cells (20,21). To investi-
gate whether the mifepristone-induced C31.L2.MiBD
recombinase has retained properties of site-directed gene
insertion into hotspot sites, we analyzed puromycin-
resistant clones for insertions into the 19q13.31 pseudo
site (21). We pooled colonies obtained by C31- and
C31.L2.MiBD-directed gene insertion and screened
genomic DNA from these pools by PCR analysis using
primers annealing to the inserted vector and to sequences
ﬂanking the 19q13.31 site (Figure 4A). Among 10
Figure 4. Analysis of C31.MiBD-mediated gene insertion at pseudo attP site 19q13.31. (A) Schematic representation of C31-mediated insertion of
attB donor plasmid into the 19q13.31 pseudo attP site in HEK-293 cells. The pAttB/PGK-puro contains an attB site and a puromycin resistance
gene driven by a PGK promoter. C31-mediated recombination between the attB site in the donor plasmid and the 19q13.31 hotspot pseudo site in
HEK-293 cells will lead to insertion of the donor plasmid into the hotspot site in either a forward or reverse orientation. The black arrows indicate
vector- and locus-speciﬁc primers. (B) Detection of C31.MiBD-mediated gene insertion at pseudo attP site 19q13.31. A total of 1.5mg of pAttB/
PGK-puro was cotransfected with 1.5mg pCMV-C31 or pCMV-C31.MiBD into HEK-293 cells. Cells were selected by treatment with puromycin,
and after 10 days of selection resistant colonies were pooled. Genomic DNA from pooled colonies was screened by PCR analysis using vector- and
locus-speciﬁc primers.
Figure 3. Inducibility of each of the six tested integration systems. The
index value for each system is calculated by dividing the number of
puromycin-resistant colonies obtained in the presence of mifepristone
with the number of colonies obtained in the absence of mifepristone
(data taken from Figures 1F and 2). All index values were determined
by colony-forming assays in HeLa cells, except for the activity of Flp
that was analyzed in HEK-293-derived cells.
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C31-mediated gene insertion, nine pools were found to
contain insertions in both orientations in this particular
site (Figure 4B). In one pool, we could detect an insertion
in only one of the two orientations. For insertions
mediated by mifepristone-induced C31.MiBD protein
the pools on average consisted of  25 clones. Among 10
analyzed pools, one or more insertions in the ﬁrst of the
two orientations could be detected in six pools, whereas
ﬁve pools contained at least one insertion in the opposite
orientation. In consideration of the diﬀerent numbers of
screened colonies with the wild-type and the inducible
integrase, our ﬁndings suggest that the speciﬁcity of
C31.L2.MiBD, allowing insertion in a previously
identiﬁed hotspot, is unaltered in comparison with the
unfused C31 recombinase. However, based on these
ﬁndings we cannot formally exclude the possibility that
the induced C31 integrase may have altered recombino-
genic properties that reduce or increase its site-selectivity.
Inducible gene insertion by a (C31 recombinase
C-terminally fused with theER
T2 domain
Tight regulation of tyrosine recombinases fused to the
modiﬁed estrogen receptor hormone-binding domain,
ER
T2, has previously been reported (30). We therefore
wanted to develop a C31 fusion variant containing a
C-terminallyfusedER
T2domainandcompareinductionof
this variant by 4-OHT with mifepristone-based induction
of C31.L2.MiBD. We exchanged the MiBD sequence in
pCMV-C31.L2.MiBD with the ER
T2 sequence, creating
a novel fusion construct, pCMV-C31.L2.ER
T2.I n
colony-forming assays using pAttB/PGK-puro as sub-
strate, transfected cells were cultivated in medium contain-
ing 500nM mifepristone or 500nM 4-OHT for induction
of the C31.L2.MiBD and C31.L2.ER
T2 variants,
respectively. Transfections with plasmid DNA encoding
the wild-type C31 or a mutated form, mC31, were
included as positive and negative controls, respectively. As
illustrated in Figure 5, the patterns of induction with
mifepristone and 4-OHT were very similar. In the presence
of the drug, we detected close to 2500 colonies with
both C31.L2.MiBD and C31.L2.ER
T2. This result
indicated that the fusion variants had retained activities
that were comparable to the wild-type protein, although
the numbers of colonies obtained with wild-type
C31 and the induced fusion variants did indeed vary
statistically (P=0.008 for C31.L2.MiBD; P=0.034 for
C31.L2.ER
T2). Moreover, the presence of mifepristone
and 4-OHT induced function of the two fusion variants 14-
and 22-fold above the background (P=0.025 and
P=0.025, respectively). Notably, comparable numbers
of colonies obtained in cells treated with mC31 and the
uninduced fusion variants (P=0.11 and P=0.33 for
mC31 versus C31.L2.MiBD and C31.L2.ER
T2,
respectively) indicated that gene insertion in the absence
of the drug was not facilitated by residual function of the
fusion integrase but more likely originated from randomly
inserted plasmid DNA. In summary, we conclude that the
activity of the C31 recombinase fused with steroid-
binding domains can be tightly regulated at the post-
translational level.
DISCUSSION
Site-speciﬁc recombination mediated by tyrosine recombi-
nases—Cre or Flp—has been widely utilized to generate
speciﬁc genomic DNA rearrangements in somatic cells of
transgenic animals (1). In this report, we describe for the
ﬁrst time the development of tightly drug-regulated serine
recombinases derived from the Streptomyces phage C31
integrase. By fusing hPR891 and ER
T2 ligand-binding
domains to the C-terminus of C31 integrase, we created
variants that were, in a comparative study, inducible by a
factor of 14 and 22 in the presence of mifepristone and
tamoxifen, respectively. In the absence of the relevant
Figure 5. Steroid-directed gene insertion facilitated by C31 integrase fusion variants. A total of 1.5mg of pAttB/PGK-puro was cotransfected into
HeLa cells with 1.5mg plasmid DNA encoding the indicated variants of the C31 integrase. C31.L2.MiBD and C31.L2.ER
T2 were analyzed in
the absence of steroid (indicated by ‘ ’) or in the presence of 500nM mifepristone (left panel) and 500nM 4-OHT (right panel), respectively. All
transfections were performed as three independent experiments. The asterisks indicate signiﬁcant diﬀerences between relevant groups (P<0.05).
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are believed to be sequestered by heat-shock proteins (52)
and therefore retained in the cytoplasm. Upon drug
administration, the ligands bind to the fusion proteins,
facilitating the release of heat-shock proteins and translo-
cation of active proteins to the nucleus. Induced variants
retained between 66% and 75% of the activity of the
unmodiﬁed C31 protein and the proteins were inactive in
the absence of steroid, as measured by colony formation
assays. Inducible C31 integrase fusion variants contain-
ing diﬀerent internal linker regions could be induced to
similar levels of activity, whereas a fusion variant con-
taining an N-terminal steroid-binding domain were inac-
tive and did not respond to the drug. Furthermore, our
data suggest that mifepristone-induced C31 integrase has
retained thesame integration proﬁle as the uninduced wild-
type version of the integrase. Altogether, drug-inducible
C31 integrases possessed properties and inducibilities
comparable to the properties of the steroid-induced
tyrosine recombinases, in this study represented by a
mifepristone-induced variant of Flp that has not pre-
viously been described.
The C31 integrase is active in mammalian cells and
facilitates recombination between the heterotypic attB and
attP sequences. The resulting recombination sites, attL
and attR, are not substrates for the C31 integrase, and
the recombination process is therefore irreversible. For
Cre and Flp, in contrast, the recognition sites generated
after recombination are immediate substrates for excision,
rendering an integrated gene cassette vulnerable for
subsequent recombinase-directed re-excision. In this per-
spective, the C31 integrase has become an attractive
novel tool for genomic engineering. Indeed, recent ﬁnd-
ings have demonstrated that the C31 integrase mediates
eﬃcient site-speciﬁc cassette exchange in mouse embryonic
stem cells (53) and site-speciﬁc gene insertion in single-cell
mouse embryos (54) and human embryonic stem cells (55).
Moreover, expression of the C31 integrase appears to be
compatible with normal mouse development (53). Hence,
we envision that strictly controlled inducible versions of
the C31 integrase could be of important use together
with Cre and/or Flp in more complex schemes of genomic
engineering, providing more sophisticated options for
genetic alterations such as sequential deletion or insertion
of transgenes (e.g. selective marker genes) in somatic cells.
Such applications will require generation of transgenic
mice expressing regulatable variants of the C31
integrase.
Site-directed insertion of attB-tagged plasmid DNA
into pseudo-attP sites in the genome has made the C31
integrase-directed gene insertion an attractive option for
persistent nonviral gene therapy. Indeed, the system has
been shown to facilitate in vivo gene insertion in a range of
tissues including mouse liver (56–58) and muscle (59) as
well as rat retina (60) and rabbit joints (61). However,
recent ﬁndings suggest that the system might be harnessed
by a tendency to cause DNA rearrangement, deletions
and interchromosomal translocations (21,56,62), possibly
caused by integrase-directed recombination between
genomic pseudo sites. It is not yet clear if such genomic
abnormalities are caused by high levels of C31 integrase
in cell culture or if such events may occur also in vivo as a
result of a transient boost or prolonged expression of the
C31 integrase. Investigations of steroid-directed induc-
tion of C31 integrase activity may shed further light on
these issues and suggest use of inducible nonviral systems
to enhance safety. In any case, a regulatable approach will
allow the protein to act in a predetermined time window,
which can be determined by administration of synthetic
steroids.
Binding of steroids to hPR891- and ER
T2-containing
fusion proteins would in theory allow the use of steroid-
binding domains for posttranslational regulation of a
variety of proteins with catalytic activities in the nucleus.
Indeed, a mifepristone-regulated fusion variant of the
adeno-associated virus Rep protein and a tamoxifen-
inducible variant of the PB transposase have been shown
to facilitate drug-dependent gene insertion (63,64). In the
present study, we investigated steroid-directed induction of
SB, FP, PB and Tol2 transposases. Using a ﬂexible linker
consisting of six amino acids, we showed that the modiﬁed
Tc1/mariner transposases, derived from SB and FP, as well
as the PB transposase could not be regulated by
mifepristone, whereas the activity of the Tol2 transposase
fused C-terminally to the steroid-binding domain was
upregulated in the presence of mifepristone. However, the
Tol2 fusion variant also showed a high basal level of
activity in the absence of the drug, indicating that further
genetic optimizations would be required to obtain tightly
regulated proteins with negligible activity in the absence of
mifepristone. Previous ﬁndings have suggested that the PB
transposase appears to be structurally ﬂexible, allowing
fusion with alternative protein domains, like DNA-binding
domains, without losing its catalytic activity (65,66).
However, in a previous study only one of three tested PB
transposase-ER
T2 fusion variants, each containing diﬀer-
ent linkers between the two domains, was found to be
active in the presence of tamoxifen (64). Our ﬁndings con-
ﬁrm that short linkers in the context of a PB transposase
fusion result in proteins with low drug inducibility.
Recent data have demonstrated that SB transposases
containing N-terminal fusion domains can retain transpo-
sition activity albeit with reduced eﬃciency (28,29,67).
We have previously developed functional fusion transpo-
sases based on the hyperactive HSB3 variant and have
veriﬁed their production by western blotting (Sharma,N.,
Moldt,B., Mikkelsen,J.G., unpublished observations).
Thus, the lack of activity of MiBD-containing variants
most likely reﬂects speciﬁc structural alterations, render-
ing the fusion protein inactive. In case of the Tol2
transposase, a previous attempt to create a fusion variant
was unsuccessful (66). As a demonstration of diﬃculties
predicting the catalytic status of transposase fusions, we
detected robust insertional activities of the Tol2 transpo-
sase tagged C-terminally with MiBD. Although this fusion
was also somewhat active in the absence of mifepristone
and therefore not tightly regulated, our results suggest
that the Tol2 transposase is indeed ﬂexible and may
remain active as part of a fusion protein.
Our studies demonstrate eﬃcient posttranslational
induction of tyrosine and serine recombinases, which
appear more functionally and structurally ﬂexible than the
e67 Nucleic Acids Research, 2008, Vol. 36, No. 11 PAGE 10 OF12various tested transposon systems. We believe that the
inducible C31 integrase, in particular, will ﬁnd use not
only in future transgenesis applications but also in impor-
tant safety studies of the C31 integrase for therapeutic
gene transfer.
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